Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
Andrew Satlin, MD
Advertisement
Articles by Andrew Satlin, MD
Advertisement
Latest Updated Articles
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer DiseasePublished: July 23rd 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease
2
Implications of Newborn Screening for Duchenne Muscular Dystrophy Care: Brenda L. Wong, MD; Michael Kelly, PhD
3
FDA Clears Pilavapadin for Phase 3 Development in Diabetic Peripheral Neuropathic Pain
4
Managing Postpartum MS: Safety Data, Relapse Risk, and Real-World Practice
5